Report | 10 July 2019 | Download PDF
In the last year, Health Action International (HAI) has continued to respond to medicines policy issues at local, regional and international levels. The work being done within the European Union has struck a note at the highest levels of decision making on some of the most pressing issues facing the lawmakers and regulators, HAI’s disease-specific projects, which challenge the lack of access to insulin and work to improve snakebite prevention and treatment measures, now lead the field in research, evidence and policy intervention. In just four years, HAI’s Addressing the Challenge and Constraints of Inuslin Sources and Supply (ACCISS) Study has uncovered the key barriers to global insulin access. Last year, entering the second phase of the study, ACCISS launched a number of evidence-based tools that are being piloted across three low- and middle-income countries. HAI significantly contributed to getting snakebite envenoming on the World Health Organization’s (WHO) ‘Category A’ list of neglected tropical diseases. In 2018, HAI was also successful in securing a World Health Assembly resolution on snakebite envenoming. That work culminates in 2019 in a Roadmap to alleviate the social and economic burden of snakebite. This year, HAI hosted a meeting to put the urgent issue of access to Internationally Controlled Essential Medicines on the international agenda, and put an end to needless suffering and pain experienced by huge numbers of people around the world.
In this Annual Report, you will discover more about HAI’s work, structure and staff, and how we put access at the heart of medicines policy.
Read the full report here